IsoStent heads for hot stent trial
This article was originally published in Clinica
Executive Summary
The FDA has granted IsoStent permission to undertake a Phase I US trial of its radioactive stent technology. Radioactive Palmaz-Schatz stents will be implanted in 30 patients to check the safety of using low-level ionising radiation to prevent neointimal proliferation after coronary artery placement.